Oct 7 (Reuters) - AstraZeneca said on Monday it would pay up to $1.9 billion to CSPC Pharmaceutical Group Ltd
in an exclusive license agreement to boost the Anglo-Swedish drugmaker's cardiovascular pipeline.
CSPC will get an upfront payment of $100 million to develop an early-stage, novel small molecule Lipoprotein (a) disruptor that could offer benefits to patients with dyslipidaemia, a disease characterised by elevated levels of so-called bad cholesterol, AstraZeneca said.
(Reporting by Yadarisa Shabong in Bengaluru)
((Yadarisa.Shabong@thomsonreuters.com; +91 9742735150;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。